FDA Updates Lumateperone Label With Relapse-Prevention Data - Poll - MDSpire

FDA Updates Lumateperone Label With Relapse-Prevention Data

Label update incorporates randomized withdrawal trial findings showing delayed time to relapse and consistent safety profile in schizophrenia

  • By

  • Kathryn Wighton

  • April 29, 2026

  • 2 min

Share

Original Source(s)

FDA Updates Lumateperone Label With Relapse-Prevention Data

  • by Kathryn Wighton

  • April 29, 2026

Related Content

Sleep Program Shifted Teen Circadian Timing

Two-week chronotherapy trial evaluates circadian phase, sleep duration, and alignment outcomes.

The many manifestations of magical thinking: a systematic review

Could Digital Twins Forecast Forensic Risk?

Researchers outline a proposed three-level framework spanning patient monitoring, ward operations, and forensic system planning.